CTOs on the Move

Freenome

www.freenome.com

 
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.freenome.com
  • 259 East Grand Avenue Suite 3434
    South San Francisco, CA USA 94080
  • Phone: 831.704.6883

Executives

Name Title Contact Details

Funding

Freenome raised $65M on 03/01/2017
Freenome raised $160M on 07/24/2019
Freenome raised $270M on 08/26/2020

Similar Companies

Styker Biotech

Styker Biotech is a West Lebanon, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galecto

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.

Myriad

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

Atmofizer

The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.

BridgeBio

We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.